Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2653-2658

  Lipton, Allan ^a   Leitzel, Kim ^a   Chaudri Ross, Hilary A ^a   Evans, Dean B ^a   Ali, Suhail M ^a   Demers, Laurence ^a   Hamer, Peter ^a   Brown Shimer, Sheryl ^a   Pierce, Karen ^a   Gaur, Victor ^a   Carney, Walter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT RESPONSE; BLOOD; BREAST TUMOR; METASTASIS; MIDDLE AGED; POSTMENOPAUSE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRIAZOLES;

EID: 45749156882     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.4336     Document Type: Article

References (31)

1. Lipton A, Ali SM, Leitzel K, et al: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21:1967-1972, 2003
2. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
3. Remacle AG, Noel A, Duggan, C, et al: Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer 77:926-931, 1998
4. Rha SY, Yang WI, Kim, JH, et al: Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5:875-879, 1998
5. Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis, and angiogenesis. Eur Respir J 7:2062-2072, 1994
6. Apte SS, Olsen BR, Murphy G: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Bio Chem 270:14313-14318, 1995
7. Goldberg GI, Strongin A, Collier IE, et al: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase and activation of the proenzyme with stromelysin. J Biol Chem 267:4583-4591, 1992
8. Cox G, Steward WP, O'Bryne KJ: The plasmin cascade and matrix metalloproteinases in nonsmall cell lung cancer. Thorax 54:169-179, 1999
9. Brew K, Dinakarpandian D, Nagase N: Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochem Biophys Acta 1477:267-283, 2000
10. Bertaux B, Hornebeck W, Eisen AZ, et al: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97:679-685, 1991
11. Hayakawa T, Yamashita K, Tanzawa, K, et al: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells: A possible new growth factor in serum. FEBS Lett 298:29-32, 1992
12. Alexander CM, Howard EW, Bissell MJ, et al: Rescue of mammary epithelial apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol 135:1669-1677, 1996
13. Li G, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59:6267-6275, 1999
14. Guedez L, Stetler-Stevenson WG, Wolff L, et al: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Investig 102:2002-2010, 1998
15. Gasson JC, Golde DW, Kaufman SE, et al: Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature (Lond) 315:768-771, 1985
16. Yoshiji J, Harris SR, Raso, E, et al: Mammary carcinoma cells overexpressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75:81-87, 1998
17. Laleur MA, Handsley MM, Knauper V, et al: Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type matrix metalloproteinases (MT-MMPs). J Cell Sci 115:3427-3428, 2002
18. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al: Matrix metalloproteinases in carcinoma of unknown primary. Cancer 104:2282-2287, 2005
19. Zeng ZS, Cohen AM, Zhang ZF, et al: Elevated tissue inhibitor of metalloproteinase I RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1:899-906, 1995
20. Mimori K, Mori M, Shiraishi T, et al: Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76:531-536, 1997
21. Gouyer V, Conti M, Devos P, et al: Tissue inhibitor of metalloproteinase-1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. Cancer 103:1676-1684, 2005
22. Ree AH, Florenes VA, Berg JP, et al: High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3:1623-1628, 1997
23. Guedez L, McMarlin AJ, Kingma DW, et al: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects of tumor growth and angiogenesis. Am J Pathol 158:1207-1215, 2001
24. Schroll A-S, Holten-Andersen MN, Peters HA, et al: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Ca Res 10:2289-2298, 2004
25. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Ca Res 6:4292-4299, 2000
26. Lipton A, Ali SM, Leitzel K, et al: Elevated plasma TIMP-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109:1933-1939, 2007
27. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
28. International Union Against Cancer: Manual of adult and pediatric medical oncology, in Monfardini S, Brunner K, Crowther D, et al (eds): Evaluation of the Cancer Patient and the Response to Treatment. Berlin, Germany, Springer, 1987, pp 22-38
29. Vizoso FJ, Gonzalez LO, Corte MD, et al: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96:903-911, 2007
30. Holten-Anderson MN, Nikolaj M, Nielsen HJ, et al: Tissue inhibitor of metalloproteinases-1 in the post-operative monitoring of colorectal cancer. Eur J Cancer 42:1889-1896, 2006
31. Sorensen MN, Bystrom P, Christensen IJ, et al: TIMP-1 is significantly associated with objective response and survival in metaststic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13:4117-4122, 2007